Arias-Guillén Marta, González Juan Carlos, Betancourt Loreley, Coll Elisabeth, Collado Silvia, Romano-Andrioni Bárbara, Lupiañez-Barbero Ascensión, Garro Julia, Duarte Verónica, Soler-Majoral Jordi, Calabia Jordi
Renal Transplantation and Nephrology Department, Hospital Clinic Barcelona, 08036 Barcelona, Spain.
Nephrology Department, Hospital de Mollet, 08100 Barcelona, Spain.
Nutrients. 2024 Nov 24;16(23):4018. doi: 10.3390/nu16234018.
To evaluate the effectiveness and safety of intradialytic parenteral nutrition (IDPN) on different nutritional outcomes.
This was a retrospective analysis for a "routinely collected data bank" in a multicenter cohort, conducted on consecutive malnourished or at-risk of malnutrition patients with chronic kidney disease on hemodialysis who underwent IDPN with a three-in-one parenteral nutrition formula for a period ≥ 2 weeks. The primary endpoint was the mean change in the malnutrition inflammation score (MIS) score between baseline and the last follow-up visit on IDPN.
Fifty-six patients were included. The mean age was 72.4 ± 12.0 years, and 24 (42.9%) were women. In the overall study sample, MIS significantly decreased from 16.4 (95%CI: 15.3-17.65) at baseline to 14.3 (95%CI: 12.8-15.8) at the last follow-up visit on IDPN ( = 0.0019). Fifteen (26.8%) patients achieved a MIS reduction ≥ 5 points after IDPN. As compared to baseline, IDPN significantly reduced the proportion of patients with protein-energy wasting (PEW) (89.3% versus 66.1%, respectively, = 0.0023). Regarding analytical parameters, serum albumin ( = 0.0003) and total proteins ( = 0.0024) significantly increased after IDPN administration. Throughout the study's follow-up period, 45 (80.4%) patients reported experiencing some type of adverse event.
IDPN was associated with a significant improvement in the nutritional profile. Notably, our research found that the administration of IDPN over a duration > 3 months significantly improved the nutritional status of patients evaluated by the MIS test.
评估透析期间肠外营养(IDPN)对不同营养结局的有效性和安全性。
这是一项对多中心队列中“常规收集数据库”的回顾性分析,研究对象为连续入选的营养不良或有营养不良风险的慢性肾脏病血液透析患者,这些患者接受了为期≥2周的三合一肠外营养配方的IDPN治疗。主要终点是IDPN治疗基线至最后一次随访期间营养不良炎症评分(MIS)的平均变化。
共纳入56例患者。平均年龄为72.4±12.0岁,女性24例(42.9%)。在整个研究样本中,MIS从基线时的16.4(95%CI:15.3 - 17.65)显著降至IDPN最后一次随访时的14.3(95%CI:12.8 - 15.8)(P = 0.0019)。15例(26.8%)患者在IDPN治疗后MIS降低≥5分。与基线相比,IDPN显著降低了蛋白质能量消耗(PEW)患者的比例(分别为89.3%和66.1%,P = 0.0023)。关于分析参数,IDPN给药后血清白蛋白(P = 0.0003)和总蛋白(P = 0.0024)显著升高。在整个研究随访期间,45例(80.4%)患者报告经历了某种类型的不良事件。
IDPN与营养状况的显著改善相关。值得注意的是,我们的研究发现,持续>3个月的IDPN给药通过MIS测试评估可显著改善患者的营养状况。